EANM 2025: 225Ac-SSO110 Data Supports the Advancement for ES-SCLC and MCC
“These oral presentations demonstrate Ariceum’s commitment to leading innovation in targeted radiotherapeutics,” said Germo Gericke, MD, Chief Medical Officer of Ariceum Therapeutics. “For the first time, we are presenting data showing minimal in-vivo redistribution of daughter radionuclides with 225Ac-SSO110, a non-internalizing SSTR2 antagonist, an important advance in our understanding of targeted alpha therapy. In parallel, our SANTANA-225 study showcases an innovative, first‑in-class approach for patients with ES‑SCLC and MCC. With the SANTANA-225 initial safety readout expected in 2026 and preliminary efficacy in 2027, we remain committed to setting new standards in both research and patient care for diseases with high unmet needs.”
Share:
More News
“This research collaboration with AbCellera directly aligns with Jazz’s rare disease strategy, expanding our focus on GI cancers and building on our existing expertise in oncology,” said Josh Allen, Ph.D., chief scientific officer, oncology, Jazz Pharmaceuticals. “We look forward to collaborating with AbCellera to progress potential best-in-class TCE multispecific antibodies
AIM Chief Executive Officer Thomas K. Equels stated: “AIM hopes to utilize the exploratory biomarker data generated through DURIPANC to design a Phase 3 study involving Ampligen in the treatment of pancreatic cancer. We are particularly interested in evaluating whether specific biomarkers may help to identify ‘super-responder’ patient subsets most
“We are committed to improving the treatment of glioblastoma and are grateful to our investigators and the patients and families who made the TRIDENT trial possible,” said Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer, Novocure. “The study did not meet its primary endpoint, but the results from TRIDENT
“Fast Track Designation is a valuable step forward for givastomig and for patients with first-line HER2-negative metastatic gastric cancer,” said Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge. “Phase 1b results demonstrate robust efficacy and favorable overall tolerability in combination with immunochemotherapy. Responses were deep and durable across a